Baricitinib (BARI), a JAK inhibitor, has been extensively used worldwide for conditions like rheumatoid arthritis, alopecia areata, atopic dermatitis, juvenile idiopathic arthritis, and COVID-19. An estimated 1,836,600 patients have been exposed to BARI in real-world settings, with 57% for COVID-19 treatment. Clinical trials have involved 14,660 subjects, including 866 patients under 18 years. The trials cover diverse racial backgrounds and age groups, from less than 1 month to over 65 years. While these exposures don't confirm efficacy or safety, they help establish BARI's overall profile and inform its performance across various populations.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.